Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 216

1.

Improved Androgen Receptor Splice Variant 7 Detection Using a Highly Sensitive Assay to Predict Resistance to Abiraterone or Enzalutamide in Metastatic Prostate Cancer Patients.

Maillet D, Allioli N, Peron J, Plesa A, Decaussin-Petrucci M, Tartas S, Ruffion A, Crouzet S, Rimokh R, Gillet PG, Freyer G, Vlaeminck-Guillem V.

Eur Urol Oncol. 2019 Oct 29. pii: S2588-9311(19)30136-1. doi: 10.1016/j.euo.2019.08.010. [Epub ahead of print]

PMID:
31676281
2.

Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer.

González-Martín A, Pothuri B, Vergote I, DePont Christensen R, Graybill W, Mirza MR, McCormick C, Lorusso D, Hoskins P, Freyer G, Baumann K, Jardon K, Redondo A, Moore RG, Vulsteke C, O'Cearbhaill RE, Lund B, Backes F, Barretina-Ginesta P, Haggerty AF, Rubio-Pérez MJ, Shahin MS, Mangili G, Bradley WH, Bruchim I, Sun K, Malinowska IA, Li Y, Gupta D, Monk BJ; PRIMA/ENGOT-OV26/GOG-3012 Investigators.

N Engl J Med. 2019 Dec 19;381(25):2391-2402. doi: 10.1056/NEJMoa1910962. Epub 2019 Sep 28.

PMID:
31562799
3.

Clinical efficacy of the optimal biological dose in early-phase trials of anti-cancer targeted therapies.

Corbaux P, El-Madani M, Tod M, Péron J, Maillet D, Lopez J, Freyer G, You B.

Eur J Cancer. 2019 Oct;120:40-46. doi: 10.1016/j.ejca.2019.08.002. Epub 2019 Aug 31. Review.

PMID:
31479946
4.

Actionable molecular alterations in advanced gynaecologic malignancies: updated results from the ProfiLER programme.

Varnier R, Le Saux O, Chabaud S, Garin G, Sohier E, Wang Q, Paindavoine S, Pérol D, Baudet C, Attignon V, Pissaloux D, Heudel P, You B, Leyronnas C, Collard O, Trédan O, Bonnin N, Long J, Jacquin JP, Cassier PA, Derbel O, Freyer G, Viari A, Blay JY, Ray-Coquard I.

Eur J Cancer. 2019 Sep;118:156-165. doi: 10.1016/j.ejca.2019.06.017. Epub 2019 Jul 24.

PMID:
31351267
5.

[CHIP and ovarian cancer].

Lécuru F, Bakrin N, Classe JM, Colombo PE, Ferron G, Freyer G, Glehen O, Gouy S, Huchon C, Narducci F, Pocard M, Pomel C, Rouzier R.

Gynecol Obstet Fertil Senol. 2019 Sep;47(9):617-618. doi: 10.1016/j.gofs.2019.06.007. Epub 2019 Jun 26. French. No abstract available.

PMID:
31252153
6.

Rates of asymptomatic respiratory virus infection across age groups.

Galanti M, Birger R, Ud-Dean M, Filip I, Morita H, Comito D, Anthony S, Freyer GA, Ibrahim S, Lane B, Matienzo N, Ligon C, Rabadan R, Shittu A, Tagne E, Shaman J.

Epidemiol Infect. 2019 Jan;147:e176. doi: 10.1017/S0950268819000505.

7.

Early Modeled Longitudinal CA-125 Kinetics and Survival of Ovarian Cancer Patients: A GINECO AGO MRC CTU Study.

Colomban O, Tod M, Leary A, Ray-Coquard I, Lortholary A, Hardy-Bessard AC, Pfisterer J, Du Bois A, Kurzeder C, Burges A, Péron J, Freyer G, You B.

Clin Cancer Res. 2019 Sep 1;25(17):5342-5350. doi: 10.1158/1078-0432.CCR-18-3335. Epub 2019 Apr 1.

PMID:
30936122
8.

Longitudinal active sampling for respiratory viral infections across age groups.

Galanti M, Birger R, Ud-Dean M, Filip I, Morita H, Comito D, Anthony S, Freyer GA, Ibrahim S, Lane B, Ligon C, Rabadan R, Shittu A, Tagne E, Shaman J.

Influenza Other Respir Viruses. 2019 May;13(3):226-232. doi: 10.1111/irv.12629. Epub 2019 Feb 15.

9.

Changes in the Use of Comprehensive Geriatric Assessment in Clinical Trials for Older Patients with Cancer over Time.

Le Saux O, Falandry C, Gan HK, You B, Freyer G, Péron J.

Oncologist. 2019 Aug;24(8):1089-1094. doi: 10.1634/theoncologist.2018-0493. Epub 2019 Feb 1.

10.

Non-pegylated liposomal doxorubicin (NPLD, Myocet®) + carboplatin in patients with platinum sensitive ovarian cancers: A ARCAGY-GINECO phase IB-II trial.

Romeo C, Joly F, Ray-Coquard I, El Kouri C, Mercier-Blas A, Berton-Rigaud D, Kalbacher E, Cojocarasu O, Fabbro M, Cretin J, Zannetti A, Abadie-Lacourtoisie S, Mollon D, Hardy-Bessard AC, Provansal M, Blot E, Delbaldo C, Lesoin A, Freyer G, You B.

Gynecol Oncol. 2019 Jan;152(1):68-75. doi: 10.1016/j.ygyno.2018.10.043. Epub 2018 Nov 14.

PMID:
30446275
11.

Phase 1b Study of Trebananib Plus Paclitaxel and Trastuzumab in Patients With HER2-Positive Locally Recurrent or Metastatic Breast Cancer.

Kaufman PA, Wildiers H, Freyer G, Kemeny M, Gonçalves A, Jerusalem G, Stopeck A, Vrindavanam N, Dalenc F, Nanayakkara N, Wu B, Pickett CA.

Clin Breast Cancer. 2019 Feb;19(1):47-57. doi: 10.1016/j.clbc.2018.09.012. Epub 2018 Oct 9.

PMID:
30420181
12.

Long-term survival in patients with epithelial ovarian cancer following cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC).

Le Saux O, Decullier E, Freyer G, Glehen O, Bakrin N.

Int J Hyperthermia. 2018;35(1):652-657. doi: 10.1080/02656736.2018.1518544. Epub 2018 Oct 8.

PMID:
30295114
13.

Over-adherence to capecitabine: a potential safety issue in breast and colorectal cancer patients.

Le Saux O, Bourmaud A, Rioufol C, Colomban O, Guitton J, Schwiertz V, Regnier V, You B, Ranchon F, Maraval-Gaget R, Girard P, Chauvin F, Freyer G, Tod M, Henin E, Trillet-Lenoir V.

Cancer Chemother Pharmacol. 2018 Aug;82(2):319-327. doi: 10.1007/s00280-018-3612-x. Epub 2018 Jun 15.

PMID:
29948022
14.

Total Hip Arthroplasty for Periacetabular Metastatic Disease. An Original Technique of Reconstruction According to the Harrington Classification.

Wegrzyn J, Malatray M, Al-Qahtani T, Pibarot V, Confavreux C, Freyer G.

J Arthroplasty. 2018 Aug;33(8):2546-2555. doi: 10.1016/j.arth.2018.02.096. Epub 2018 Mar 17.

PMID:
29656965
15.

[Expectation about maintenance therapy among the GINECO French ovarian cancer cohort from the European NOGGO/ENGOT-ov22 Expression IV survey].

Lorcet M, Lortholary A, Kurtz JE, Berton-Rigaud D, Fabbro M, De La Motte Rouge T, Kaminsky-Forrett MC, Floquet A, Freyer G, Combe P, Dohollou N, Kalbacher E, Despax R, Largillier R, Hardy Bessard AC, Gane N, Sehouli J, Oskay-Oezcelik G, Licaj I, Ray-Coquard I, Joly Lobbedez F.

Bull Cancer. 2018 May;105(5):465-474. doi: 10.1016/j.bulcan.2018.01.015. Epub 2018 Mar 12. French.

PMID:
29544693
16.

Impact of geriatric assessment for the therapeutic decision-making of breast cancer: results of a French survey. AFSOS and SOFOG collaborative work.

Falandry C, Krakowski I, Curé H, Carola E, Soubeyran P, Guérin O, Gaudin H, Freyer G.

Breast Cancer Res Treat. 2018 Apr;168(2):433-441. doi: 10.1007/s10549-017-4607-8. Epub 2017 Dec 14.

PMID:
29243107
17.

Palbociclib-Induced Thrombotic Microangiopathy in Metastatic Breast Cancer Patient Surviving for 18 Years: Case Report and Review of the Literature.

Raiss H, Péron J, Tartas S, Trillet-Lenoir V, Freyer G, Errihani H.

Clin Breast Cancer. 2018 Jun;18(3):e263-e266. doi: 10.1016/j.clbc.2017.10.001. Epub 2017 Oct 7. Review. No abstract available.

PMID:
29153774
18.

Evaluation of pre-analytical conditions and comparison of the performance of several digital PCR assays for the detection of major EGFR mutations in circulating DNA from non-small cell lung cancers: the CIRCAN_0 study.

Garcia J, Dusserre E, Cheynet V, Bringuier PP, Brengle-Pesce K, Wozny AS, Rodriguez-Lafrasse C, Freyer G, Brevet M, Payen L, Couraud S.

Oncotarget. 2017 Sep 21;8(50):87980-87996. doi: 10.18632/oncotarget.21256. eCollection 2017 Oct 20.

19.

Changes in the use of end points in clinical trials for elderly cancer patients over time.

Le Saux O, Falandry C, Gan HK, You B, Freyer G, Péron J.

Ann Oncol. 2017 Oct 1;28(10):2606-2611. doi: 10.1093/annonc/mdx354.

20.

Traitement des rechutes tardives du cancer de l’ovaire.

Floquet A, Berton-Rigaud D, Ferron G, Freyer G, Hardy-Bessard AC, You B.

Bull Cancer. 2017 May;104 Suppl 1:S24-S31. doi: 10.1016/S0007-4551(17)30159-5. French.

PMID:
28625312
21.

[Evolution of reimbursement of high-cost anticancer drugs: Financial impact within a university hospital].

Baudouin A, Fargier E, Cerruti A, Dubromel A, Vantard N, Ranchon F, Schwiertz V, Salles G, Souquet PJ, Thomas L, Bérard F, Nancey S, Freyer G, Trillet-Lenoir V, Rioufol C.

Bull Cancer. 2017 Jun;104(6):538-551. doi: 10.1016/j.bulcan.2017.01.006. Epub 2017 Feb 23. French.

PMID:
28237353
22.

EVESOR, a model-based, multiparameter, Phase I trial to optimize the benefit/toxicity ratio of everolimus and sorafenib.

El-Madani M, Colomban O, Tod M, Maillet D, Peron J, Rodriguez-Lafrasse C, Badary OA, Valette PJ, Lefort T, Cassier P, El-Shenawy SM, El-Demerdash E, Hommel-Fontaine J, Guitton J, Gagnieu MC, Ibrahim BM, Barrois C, Freyer G, You B.

Future Oncol. 2017 Apr;13(8):679-693. doi: 10.2217/fon-2016-0357. Epub 2017 Jan 12.

PMID:
28076966
23.

PD-L1 Expression in Premalignant and Malignant Trophoblasts From Gestational Trophoblastic Diseases Is Ubiquitous and Independent of Clinical Outcomes.

Bolze PA, Patrier S, Massardier J, Hajri T, Abbas F, Schott AM, Allias F, Devouassoux-Shisheboran M, Freyer G, Golfier F, You B.

Int J Gynecol Cancer. 2017 Mar;27(3):554-561. doi: 10.1097/IGC.0000000000000892.

PMID:
28060141
24.

New insights into the role of the porcine intestinal yeast, Kazachstania slooffiae, in intestinal environment of weaned piglets.

Urubschurov V, Büsing K, Freyer G, Herlemann DP, Souffrant WB, Zeyner A.

FEMS Microbiol Ecol. 2017 Feb;93(2). pii: fiw245. doi: 10.1093/femsec/fiw245. Epub 2016 Dec 8.

PMID:
27940642
25.

Motivations of patients seeking supportive care for cancer from physicians prescribing homeopathic or conventional medicines: results of an observational cross-sectional study.

Danno K, Colas A, Freyer G, Guastalla JP, Duru G, Musial E, Libourel V, Fendler JP, Masson JL, Bordet MF.

Homeopathy. 2016 Nov;105(4):289-298. doi: 10.1016/j.homp.2016.09.001. Epub 2016 Oct 24.

26.

Inclusion of elderly patients in oncology clinical trials.

Le Saux O, Falandry C, Gan HK, You B, Freyer G, Péron J.

Ann Oncol. 2016 Sep;27(9):1799-804. doi: 10.1093/annonc/mdw259. Epub 2016 Jun 29.

PMID:
27358382
27.

[Clinical burden caused by hospitalization for febrile neutropenia in France in 2010-2011: An analysis of the PMSI database].

Freyer G, Scotte F, Borget I, Bruyas A, Vainchtock A, Chouaid C.

Bull Cancer. 2016 Jun;103(6):552-60. doi: 10.1016/j.bulcan.2016.03.012. Epub 2016 May 24. French.

PMID:
27233367
28.

Prognostic factors for overall survival in elderly patients with advanced ovarian cancer treated with chemotherapy: Results of a pooled analysis of three GINECO phase II trials.

Tinquaut F, Freyer G, Chauvin F, Gane N, Pujade-Lauraine E, Falandry C.

Gynecol Oncol. 2016 Oct;143(1):22-26. doi: 10.1016/j.ygyno.2016.03.018. Epub 2016 Aug 25.

PMID:
27045777
29.

[Innovative anticancer agents reserved to hospital use and not involved in the hospital budget: Creation and evolution].

Freyer G, Marty M; membres du groupe de travail, Blay JY, Chauffert B, Ganem G, Lotz JP, Marchal F, Medioni J, Ray-Coquard I.

Bull Cancer. 2016 Apr;103(4):315-7. doi: 10.1016/j.bulcan.2016.02.013. Epub 2016 Mar 29. French. No abstract available.

PMID:
27036539
30.

Revisiting dosing regimen using PK/PD modeling: the MODEL1 phase I/II trial of docetaxel plus epirubicin in metastatic breast cancer patients.

Hénin E, Meille C, Barbolosi D, You B, Guitton J, Iliadis A, Freyer G.

Breast Cancer Res Treat. 2016 Apr;156(2):331-41. doi: 10.1007/s10549-016-3760-9. Epub 2016 Mar 22.

PMID:
27002506
31.

Revisiting Dosing Regimen Using Pharmacokinetic/Pharmacodynamic Mathematical Modeling: Densification and Intensification of Combination Cancer Therapy.

Meille C, Barbolosi D, Ciccolini J, Freyer G, Iliadis A.

Clin Pharmacokinet. 2016 Aug;55(8):1015-25. doi: 10.1007/s40262-016-0374-7.

PMID:
26946136
32.

First-Line Treatments for Poor-Prognosis Metastatic Renal Cell Carcinoma: Experts' Prescribing Practices and Systematic Literature Review.

Le Saux O, Freyer G, Négrier S.

Clin Drug Investig. 2016 May;36(5):389-99. doi: 10.1007/s40261-016-0384-0. Review.

PMID:
26945986
33.

Modeling and predicting optimal treatment scheduling between the antiangiogenic drug sunitinib and irinotecan in preclinical settings.

Wilson S, Tod M, Ouerdani A, Emde A, Yarden Y, Adda Berkane A, Kassour S, Wei MX, Freyer G, You B, Grenier E, Ribba B.

CPT Pharmacometrics Syst Pharmacol. 2015 Dec;4(12):720-7. doi: 10.1002/psp4.12045. Epub 2015 Dec 11.

34.

Identification of Most Aggressive Carcinoma Among Patients Diagnosed With Prostate Cancer Using Mathematical Modeling of Prostate-Specific Antigen Increases.

de Charry F, Colomban O, You B, Ruffion A, Paparel P, Wilbaux M, Tod M, Freyer G, Perrin P.

Clin Genitourin Cancer. 2016 Jun;14(3):210-217.e1. doi: 10.1016/j.clgc.2015.12.006. Epub 2015 Dec 18.

PMID:
26804605
35.

Volasertib Versus Chemotherapy in Platinum-Resistant or -Refractory Ovarian Cancer: A Randomized Phase II Groupe des Investigateurs Nationaux pour l'Etude des Cancers de l'Ovaire Study.

Pujade-Lauraine E, Selle F, Weber B, Ray-Coquard IL, Vergote I, Sufliarsky J, Del Campo JM, Lortholary A, Lesoin A, Follana P, Freyer G, Pardo B, Vidal L, Tholander B, Gladieff L, Sassi M, Garin-Chesa P, Nazabadioko S, Marzin K, Pilz K, Joly F.

J Clin Oncol. 2016 Mar 1;34(7):706-13. doi: 10.1200/JCO.2015.62.1474. Epub 2016 Jan 11.

PMID:
26755507
36.

Routine Clinical Practice for Patients With Recurrent Ovarian Carcinoma: Results From the TROCADERO Study.

Freyer G, Ray-Coquard I, Fischer D, Martín AG, Kielhorn A, Chia V, Nanayakkara N, Taylor A.

Int J Gynecol Cancer. 2016 Feb;26(2):240-7. doi: 10.1097/IGC.0000000000000590.

PMID:
26745696
37.

Telomere length is a prognostic biomarker in elderly advanced ovarian cancer patients: a multicenter GINECO study.

Falandry C, Horard B, Bruyas A, Legouffe E, Cretin J, Meunier J, Alexandre J, Delecroix V, Fabbro M, Certain MN, Maraval-Gaget R, Pujade-Lauraine E, Gilson E, Freyer G.

Aging (Albany NY). 2015 Dec;7(12):1066-76.

38.

Cross-sectional study on comorbidities and adverse events in patients with advanced and recurrent ovarian cancer in France.

Le Saux O, Taylor A, Chia V, Pillas D, Kaur M, Freyer G.

Clin Epidemiol. 2015 Oct 27;7:431-40. doi: 10.2147/CLEP.S86429. eCollection 2015.

39.

Dominance of 'Gallionella capsiferriformans' and heavy metal association with Gallionella-like stalks in metal-rich pH 6 mine water discharge.

Fabisch M, Freyer G, Johnson CA, Büchel G, Akob DM, Neu TR, Küsel K.

Geobiology. 2016 Jan;14(1):68-90. doi: 10.1111/gbi.12162. Epub 2015 Sep 26.

PMID:
26407813
40.

Etoposide pharmacokinetics impact the outcomes of lymphoma patients treated with BEAM regimen and ASCT: a multicenter study of the LYmphoma Study Association (LYSA).

You B, Salles G, Bachy E, Casasnovas O, Tilly H, Ribrag V, Sebban C, Hénin E, Guitton J, Tod M, Freyer G.

Cancer Chemother Pharmacol. 2015 Nov;76(5):939-48. doi: 10.1007/s00280-015-2866-9. Epub 2015 Sep 21.

PMID:
26391155
41.

Attitudes of physicians toward assessing risk and using granulocyte colony-stimulating factor as primary prophylaxis in patients receiving chemotherapy associated with an intermediate risk of febrile neutropenia.

Freyer G, Kalinka-Warzocha E, Syrigos K, Marinca M, Tonini G, Ng SL, Wong ZW, Salar A, Steger G, Abdelsalam M, DeCosta L, Szabo Z.

Med Oncol. 2015 Oct;32(10):236. doi: 10.1007/s12032-015-0682-z. Epub 2015 Aug 28.

PMID:
26315712
42.

A Joint Model for the Kinetics of CTC Count and PSA Concentration During Treatment in Metastatic Castration-Resistant Prostate Cancer.

Wilbaux M, Tod M, De Bono J, Lorente D, Mateo J, Freyer G, You B, Hénin E.

CPT Pharmacometrics Syst Pharmacol. 2015 May;4(5):277-85. doi: 10.1002/psp4.34. Epub 2015 Apr 24.

43.

Agreement for depression diagnosis between DSM-IV-TR criteria, three validated scales, oncologist assessment, and psychiatric clinical interview in elderly patients with advanced ovarian cancer.

Rhondali W, Freyer G, Adam V, Filbet M, Derzelle M, Abgrall-Barbry G, Bourcelot S, Machavoine JL, Chomat-Neyraud M, Gisserot O, Largillier R, Le Rol A, Priou F, Saltel P, Falandry C.

Clin Interv Aging. 2015 Jul 13;10:1155-62. doi: 10.2147/CIA.S71690. eCollection 2015.

44.

Adherence to oral anticancer chemotherapy: What influences patients' over or non-adherence? Analysis of the OCTO study through quantitative-qualitative methods.

Bourmaud A, Henin E, Tinquaut F, Regnier V, Hamant C, Colomban O, You B, Ranchon F, Guitton J, Girard P, Freyer G, Tod M, Rioufol C, Trillet-Lenoir V, Chauvin F.

BMC Res Notes. 2015 Jul 4;8:291. doi: 10.1186/s13104-015-1231-8.

45.

Prenatal Exposure to Phthalates and Childhood Body Size in an Urban Cohort.

Maresca MM, Hoepner LA, Hassoun A, Oberfield SE, Mooney SJ, Calafat AM, Ramirez J, Freyer G, Perera FP, Whyatt RM, Rundle AG.

Environ Health Perspect. 2016 Apr;124(4):514-20. doi: 10.1289/ehp.1408750. Epub 2015 Jun 12.

46.

Multiparameter Phase I trials: a tool for model-based development of targeted agent combinations--example of EVESOR trial.

El-Madani M, Hénin E, Lefort T, Tod M, Freyer G, Cassier P, Valette PJ, Rodriguez-Lafrasse C, Berger F, Guitton J, Lachuer J, Slimane K, Barrois C, You B.

Future Oncol. 2015;11(10):1511-8. doi: 10.2217/fon.15.49.

PMID:
25963428
47.

Concomitant drugs with low risks of drug-drug interactions for use in oncology clinical trials.

Ranchon F, Vial T, Rioufol C, Hénin E, Falandry C, Freyer G, Trillet-Lenoir V, Le Tourneau C, You B.

Crit Rev Oncol Hematol. 2015 May;94(2):189-200. doi: 10.1016/j.critrevonc.2014.12.014. Epub 2015 Jan 3. Review.

PMID:
25638703
48.

Optimal management of breast cancer in the elderly patient: current perspectives.

Le Saux O, Ripamonti B, Bruyas A, Bonin O, Freyer G, Bonnefoy M, Falandry C.

Clin Interv Aging. 2015 Jan 6;10:157-74. doi: 10.2147/CIA.S50670. eCollection 2015. Review.

49.

EPICC study: evaluation of pharmaceutical intervention in cancer care.

Vantard N, Ranchon F, Schwiertz V, Gourc C, Gauthier N, Guedat MG, He S, Kiouris E, Alloux C, You B, Souquet PJ, Freyer G, Salles G, Trillet-Lenoir V, Rioufol C.

J Clin Pharm Ther. 2015 Apr;40(2):196-203. doi: 10.1111/jcpt.12242. Epub 2015 Jan 16.

PMID:
25594148
50.

Open-label uncontrolled pilot study to evaluate complementary therapy with Ruta graveolens 9c in patients with advanced cancer.

Freyer G, You B, Villet S, Tartas S, Fournel-Federico C, Trillet-Lenoir V, Hamizi S, Colomban O, Chavernoz N, Falandry C.

Homeopathy. 2014 Oct;103(4):232-8. doi: 10.1016/j.homp.2014.06.001. Epub 2014 Jul 30.

Supplemental Content

Loading ...
Support Center